Study Summary
This is a first-in-human, non-randomized, open label, single treatment, Phase 1 study in approximately 7 patients with severe hemophilia A. The study will evaluate gene therapy by transplantation of autologous CD34+ hematopoietic stem cells transduced ex vivo with the CD68-ET3 lentiviral vector.
Want to learn more about this trial?
Request More InfoInterventions
Gene therapyDRUG
CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
BiologicalOTHER
G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
Study Locations
No locations listed.